Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a strong sell rating to a hold rating in a research note published on Monday morning,Zacks.com reports.

A number of other research firms have also recently weighed in on PBH. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $53.57 on Monday. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of 15.00, a PEG ratio of 1.66 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The business has a 50 day simple moving average of $49.11 and a 200-day simple moving average of $55.82. Prestige Consumer Healthcare has a 1 year low of $42.62 and a 1 year high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.09. The firm had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Equities analysts forecast that Prestige Consumer Healthcare will post 4.55 EPS for the current year.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after purchasing an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Prestige Consumer Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after buying an additional 1,289 shares during the period. Goldman Sachs Group Inc. increased its stake in Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares during the period. Jane Street Group LLC increased its stake in Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after buying an additional 70,330 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).